Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer

INTRODUCTION: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib was recently approved for resected EGFR-mutant stages IB-IIIA non-small cell lung cancer due to improved disease-free survival (DFS) in this population compared with placebo. This study aimed to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemmon, Christopher A, Zabor, Emily C, Pennell, Nathan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074960/
https://www.ncbi.nlm.nih.gov/pubmed/35285487
http://dx.doi.org/10.1093/oncolo/oyac021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074960/
https://www.ncbi.nlm.nih.gov/pubmed/35285487
http://dx.doi.org/10.1093/oncolo/oyac021

Ejemplares similares